Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRBU Caribou Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: CRBU
Price (delayed)
$1.16
Market cap
$107.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$104.69M
Highlights
Caribou Biosciences's debt has decreased by 3.4% YoY
The quick ratio is down by 28% year-on-year but it is up by 7% since the previous quarter
The revenue has dropped by 76% year-on-year and by 24% since the previous quarter
CRBU's gross profit has plunged by 76% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of CRBU
Market
Valuations
Earnings
Shares outstanding
93M
Market cap
$107.89M
Enterprise value
$104.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
14.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.84
Revenue
$7.57M
Gross profit
$7.57M
Operating income
-$165.88M
Net income
-$147.86M
EBIT
-$147.87M
EBITDA
-$141.35M
Free cash flow
-$142.18M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.53
Book value per share
$2.34
Revenue per share
$0.08
TBVPS
$2.95
Total assets
$273.66M
Total liabilities
$56.43M
Debt
$26.22M
Equity
$217.22M
Working capital
$188.83M
Debt to equity
0.12
Current ratio
7.63
Quick ratio
7.38
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-1,868.5%
Gross margin
100%
Net margin
-1,954.6%
Operating margin
-2,192.7%
Return on assets
-45.3%
Return on equity
-55.7%
Return on invested capital
-50.4%
Return on capital employed
-60.3%
Return on sales
-1,954.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBU stock price
How has the Caribou Biosciences stock price performed over time
Intraday
3.57%
1 week
-4.92%
1 month
23.61%
1 year
-33.71%
YTD
-27.04%
QTD
27.04%
Financial performance
How have Caribou Biosciences's revenue and profit performed over time
Revenue
$7.57M
Gross profit
$7.57M
Operating income
-$165.88M
Net income
-$147.86M
Gross margin
100%
Net margin
-1,954.6%
The revenue has dropped by 76% year-on-year and by 24% since the previous quarter
CRBU's gross profit has plunged by 76% YoY and by 24% from the previous quarter
The company's operating margin fell by 32% QoQ
Caribou Biosciences's net margin has decreased by 31% from the previous quarter
Price vs fundamentals
How does CRBU's price correlate with its fundamentals
Growth
What is Caribou Biosciences's growth rate over time
Valuation
What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
0.5
P/S
14.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.84
Caribou Biosciences's EPS has decreased by 11% YoY
The equity fell by 37% YoY and by 14% QoQ
The revenue has dropped by 76% year-on-year and by 24% since the previous quarter
CRBU's P/S is 14% above its last 4 quarters average of 12.5
Efficiency
How efficient is Caribou Biosciences business performance
The ROE has plunged by 67% YoY and by 11% from the previous quarter
CRBU's ROA has dropped by 62% year-on-year and by 9% since the previous quarter
CRBU's return on invested capital has dropped by 50% year-on-year and by 9% since the previous quarter
Caribou Biosciences's return on sales has decreased by 31% QoQ
Dividends
What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBU.
Financial health
How did Caribou Biosciences financials performed over time
The company's total assets fell by 33% YoY and by 13% QoQ
The quick ratio is down by 28% year-on-year but it is up by 7% since the previous quarter
Caribou Biosciences's debt is 88% less than its equity
Caribou Biosciences's debt to equity has soared by 50% YoY and by 20% from the previous quarter
The equity fell by 37% YoY and by 14% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.